U.S. Home Infusion Therapy Market Size, Share & Trends Analysis Report By Product (Infusion Pumps, Needleless Connectors), By Application (Anti-Infective, Endocrinology), And Segment Forecasts, 2022 - 2030

Report Overview

The U.S. home infusion therapy market size was estimated at USD 16.59 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.5% from 2022 to 2030. The growing elderly population prone to various severe disorders is one of the major growth drivers for the industry. In addition, the increasing prevalence of disorders, such as cancer, diabetes, chronic pain, and gastrointestinal diseases is also expected to fuel the growth. The emergence of COVID-19 increased the importance and demand for medical devices especially in a home-based setting as the virus is transmitted through physical contact. The market witnessed positive revenue increases in 2020 but key players faced supply chain bottlenecks.

However, in 2021, key players like Baxter, Option Healthcare, and Smiths Medical reported a soaring revenue increase as compared to 2020, especially in the U.S. For instance, Baxter reported an eight percent increase in sales revenue in the third quarter of 2021 as compared to 2020. Growth of 14.1% ($ 891.9 million) was reported by Option Care Health Inc in the third quarter of 2021 as compared to $781.6 in 2020. This indicates that the market is recovering at a conspicuous rate and is expected to boost further.

Home infusion therapy offers various benefits to the patient. Some of the benefits comprise cost-effectiveness, better outcomes, better convenience, and higher safety standards. As compared to hospital treatment, home infusion therapy is cost-effective since eliminates hospital stays that ultimately saves the patient’s money. Home infusion therapy also allows the patient to maintain higher safety due to less risk of hospital-acquired infections at home. This augments the demand for home treatment, thereby driving the growth of the U.S. home infusion therapy market.

Increasing patients’ preference for home therapy is also driving the industry’s growth. Home healthcare supports the daily life activities of patients and provides better access to skilled medical care. In addition, geriatric patients with chronic disorders and individuals recently discharged from hospitals and other healthcare settings are expected to be at high nutrition risk and can get home-cooked meals. These factors are expected to drive the industry’s expansion over the forecast period.

The growing advancements in the home healthcare industry are also expected to fuel the market’s growth in the forthcoming years. The availability of Point-of-care (POC) diagnostics that help in faster patient care and the provision of telehealth programs for patients suffering from chronic disorders and who need to be admitted frequently is trending.

The growing prevalence of chronic disorders in the geriatric population is also affecting the growth of the industry. As per National Council on Aging, approximately 80 percent geriatric population is affected by at least one chronic disorder, while 68 percent suffer from two disorders. Some of the common disorders prevalent in the elderly comprise arthritis (42%) and diabetes (20%).

The pandemic positively impacted the market in 2021. According to McKinsey, emergency room visits in the U.S were down by half or more and faced an accelerated decline throughout the year. This led healthcare practitioners prescribing patients home infusion treatments to monitor them remotely which is safe for the patient and also reduces the burden on a healthcare facility.

Smiths Medical stated that demand for items such as ventilators, airway management products, and infusion pumps increased substantially during the pandemic. The company’s revenue from the infusion system was up by 4%, driven by COVID-19-related demand. The safety of immune-compromised and critically ill patients, the effectiveness and low cost of home infusion services, and the low risk of transmission of the Covid-19 virus, are factors that will drive the market growth over the forecast period.

Product Insights

The infusion pumps segment held the largest revenue share of 50.8% in 2021. The infusion pumps segment is further categorized into ambulatory infusion pumps, elastomeric pumps, syringe pumps, insulin pumps, Patient Controlled Analgesics (PCA), and volumetric pumps. This can be attributed to their increasing use and efficiency in delivering nutrition, medications, and other required fluids in required amounts. In addition, modernized infusion pumps are equipped with alert systems to avoid the risk of adverse drug interaction or when the pump parameters are indifferently set. These factors are expected to drive segment growth.

The needleless connectors segment is expected to be the fastest-growing owing to various benefits, such as less risk of bacterial contamination and higher protection against needlestick injuries. Moreover, needleless connectors reduce the risk of Health-care Associated Bloodstream Infections (HA-BSIs). Owing to these features, the demand for needleless connectors is predicted to augment over the forecast period.

Application Insights

The anti-infective segment registered a significant revenue share of 27.2% in 2021. The significant share of the segment is attributed to its extensive use as an antifungal, antibiotic, and antiviral agent at-home care. Moreover, growing efforts for reducing hospital stays are also increasing the demand for anti-infective therapy, thereby driving the segment’s growth. By application, the market is divided into anti-infective, endocrinology, hydration therapy, parenteral nutrition, enteral nutrition, chemotherapy, specialty pharmaceuticals, and others.

Endocrinology is predicted to be the fastest-growing segment owing to the growing number of conditions associated with the endocrine system. The thyroid is one of the most common disorders prevalent in the U.S., sometimes resulting in death. According to the American Cancer Society, 2019, approximately 52,070 thyroid cancer cases have been registered (14,260 in males and 37,810 in females). Hence, growing cases of thyroid along with metabolic disorders in the U.S. is expected to drive the segment.

Regional Insights

Owing to the increasing number of chronic disorders prevalent in individuals and growing initiatives by the government for the advantages of home infusion therapy, the industry is expected to grow considerably. Moreover, increasing demand for long-term therapies by patients is also expected to fuel the growth in the near future.

Major factors driving the growth include an increase in the geriatric population and a rise in disease burden. In addition, growing awareness has led to a higher inclination of patients, especially the geriatric population, to require long-term care toward home infusion therapy. It has been estimated that the administration of medications at home costs from USD 150 to USD 200 per day, much lesser than the cost of a typical inpatient stay, which costs from USD 1,500 to USD 2,500 per day.

The well-established healthcare industry, easy access to healthcare needs, faster adoption of advanced technologies, and high disposable income of consumers are a few other drivers of the U.S. home infusion therapy market. The availability of superior-quality home infusion products to patients is also propelling the industry.

Key Companies & Market Share Insights

Some of the key players are focusing on adopting growth strategies, such as mergers and acquisitions, new product launches, innovations in existing technologies, and more. For instance, In December 2021, Baxter International completed the acquisition of Hillrom. This acquisition will help the company in broadening its geographic footprint and integrate medical device technology that will enhance patient care and lower costs. Also in May 2021, Smiths Medical and Ivenix, Inc. announced a partnership agreement to offer a comprehensive suite of infusion management solutions in the U.S. market. This partnership is expected to evolve infusion management to improve patient safety.

Some prominent players in the U.S. home infusion therapy market include:

• B. Braun Melsungen,

• Baxter International,

• Caesarea Medical Electronics Ltd.,

• CareFusion,

• Fresenius Kabi,

• ICU Medical,

• JMS CO., LTD.,

• Smiths Medical, Inc.,

• Terumo Corporation,

• Coram LLC,

• Option Care Enterprises, Inc.,

• BioScrip, Inc.,

• BriovaRx Infusion Services,

• Paragon Healthcare.

U.S Home infusion Market Report Scope

U.S Home infusion Market Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. home infusion therapy market report based on product and application:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Infusion pumps

    • Elastomeric

    • Electromechanical

    • Gravity

    • Others

  • Intravenous Sets

  • IV Cannulas

  • Needleless Connectors

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Anti-Infective

  • Endocrinology

    • Diabetes

    • Others

  • Hydration Therapy

    • Athletes

    • Others

  • Chemotherapy

  • Enteral Nutrition

  • Parenteral Nutrition

  • Specialty Pharmaceuticals

  • Others